Atlas Trials

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Clinical trial NCT00162812 · TERMINATED

Trial details

NCT number
NCT00162812
Sponsor
Jules Bordet Institute
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2003-01-01
Primary completion
2008-12-01
Enrollment
338

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.